Skip to content
The Policy VaultThe Policy Vault

Egrifta SV — Point32Health

Human immunodeficiency virus (HIV)-associated lipodystrophy

Initial criteria

  • Documentation the patient has excess abdominal fat secondary to human immunodeficiency virus (HIV)-associated lipodystrophy

Approval duration

24 months